Pharmaceutical Compositions Comprising Anagrelide

Patent No. EP2915526 (titled "Pharmaceutical Compositions Comprising Anagrelide") was filed by Galenicum Health SL on Mar 9, 2015. The application was issued on Jun 2, 2021.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Company	Opposition Date	Representative
HAMM & WITTKOPP	Mar 1, 2022	HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Dec 7, 2022
Communication to the parties concerning the termination of the opposition proceedings (proprietor)
Dec 2, 2022
Termination of the opposition proceedings with maintenance of patent
Aug 29, 2022
(Electronic) Receipt
Aug 29, 2022
Advice of delivery
Aug 29, 2022
Letter accompanying subsequently filed items
Aug 23, 2022
Decision to discontinue the opposition proceedings
Aug 23, 2022
Transmittal of decision / summons - opposition
Jul 22, 2022
(Electronic) Receipt
Jul 22, 2022
Auxiliary request during Opposition procedure
Jul 22, 2022
Auxiliary request during Opposition procedure - 01
Jul 22, 2022
Letter accompanying subsequently filed items
Jul 22, 2022
Reply of the patent proprietor to the notice(s) of opposition
May 25, 2022
Brief communication - Opposition proceedings
May 25, 2022
Brief communication - Opposition proceedings
May 20, 2022
(Electronic) Receipt
May 20, 2022
Letter accompanying subsequently filed items
May 20, 2022
Withdrawal of an opposition
May 2, 2022
Communication of the registration of a transfer or change of name and/or address
Apr 12, 2022
Document concerning representation
Apr 12, 2022
Submission concerning change of applicant's address
Mar 23, 2022
Notice of further oppositions to opponent(s)
Mar 4, 2022
Communication of a notice of opposition - first information to patent proprietor
Mar 1, 2022
(Electronic) Receipt
Mar 1, 2022
Citation in opposition procedure - 001
Mar 1, 2022
Citation in opposition procedure - 002
Mar 1, 2022
Citation in opposition procedure - 003
Mar 1, 2022
Citation in opposition procedure - 004
Mar 1, 2022
Citation in opposition procedure - 005
Mar 1, 2022
Citation in opposition procedure - 006
Mar 1, 2022
Citation in opposition procedure - 007
Mar 1, 2022
Citation in opposition procedure - 008
Mar 1, 2022
Citation in opposition procedure - 009
Mar 1, 2022
Citation in opposition procedure - 010
Mar 1, 2022
Consolidated list of cited opposition documents
Mar 1, 2022
Notice of opposition
Mar 1, 2022
Notice of opposition
Sep 24, 2021
Communication of amended entries concerning the representative
Sep 24, 2021
Communication of the registration of a transfer or change of name and/or address
Jun 15, 2021
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
May 7, 2021
Decision to grant a European patent
Apr 28, 2021
Information about non-relevance of third-party observations
Apr 9, 2021
(Electronic) Receipt
Apr 9, 2021
French translation of claims
Apr 9, 2021
German translation of the claims
Apr 9, 2021
Letter accompanying subsequently filed items
Mar 29, 2021
Acknowledgement of receipt of third party observations
Mar 29, 2021
Transmittal of third party observations to applicant
Mar 24, 2021
(Electronic) Receipt
Mar 24, 2021
Letter accompanying subsequently filed items
Mar 24, 2021
Non-patent literature filed by a third party
Mar 24, 2021
Non-patent literature filed by a third party
Mar 24, 2021
Non-patent literature filed by a third party
Mar 24, 2021
Non-patent literature filed by a third party
Mar 24, 2021
Non-patent literature filed by a third party
Mar 24, 2021
Observations by third parties
Mar 23, 2021
Letter accompanying subsequently filed items
Mar 23, 2021
Submission concerning change of applicant's address
Mar 23, 2021
Submission concerning change of applicant's name
Mar 2, 2021
Bibliographic data of the European patent application
Mar 2, 2021
Communication about intention to grant a European patent
Mar 2, 2021
Intention to grant (signatures)
Mar 2, 2021
Text intended for grant (clean copy)
Mar 2, 2021
Text intended for grant (version for approval)
Feb 24, 2021
Response to enquiry for communication from the Examining Division
Feb 17, 2021
Submission concerning change of applicant's address
Feb 10, 2021
(Electronic) Receipt
Feb 10, 2021
Enquiry as to when a communication from the Examining Division can be expected
Feb 10, 2021
Letter accompanying subsequently filed items
Oct 8, 2020
Communication of the registration of a transfer or change of name and/or address
Oct 2, 2020
Annexes in respect of a client data request
Oct 2, 2020
Submission concerning change of applicant's name
Aug 4, 2020
Indication of deficiencies in a request for entry of a change in personal particulars and invitation to correct them
Jul 22, 2020
Submission concerning change of applicant's name
Oct 9, 2019
(Electronic) Receipt
Oct 9, 2019
Amended claims with annotations
Oct 9, 2019
Amended claims with annotations
Oct 9, 2019
Amended claims with annotations
Oct 9, 2019
Amended description with annotations
Oct 9, 2019
Claims
Oct 9, 2019
Claims
Oct 9, 2019
Claims
Oct 9, 2019
Description
Oct 9, 2019
Letter accompanying subsequently filed items
Oct 9, 2019
Reply to communication from the Examining Division
Jun 6, 2019
Annex to the communication
Jun 6, 2019
Communication from the Examining Division
Mar 12, 2019
Decision to allow further processing
Feb 28, 2019
(Electronic) Receipt
Feb 28, 2019
Amended claims with annotations
Feb 28, 2019
Claims
Feb 28, 2019
Letter accompanying subsequently filed items
Feb 28, 2019
Reply to communication from the Examining Division
Feb 28, 2019
Request for further processing
Dec 20, 2018
Application deemed to be withdrawn (no reply to communication from the Examining Division)
Sep 21, 2018
Transmittal of third party observations to applicant
Sep 7, 2018
Observations by third parties
Jul 24, 2018
Grant of extension of time limit (examination procedure)
Jul 18, 2018
(Electronic) Receipt
Jul 18, 2018
Letter accompanying subsequently filed items
Jul 18, 2018
Request for extension of time limit to communication from the Examining Division
May 2, 2018
Annex to the communication
May 2, 2018
Communication from the Examining Division
Apr 24, 2018
Examination started
Jan 16, 2018
Notification regarding date of start of examination with possibility to withdraw
Feb 16, 2016
(Electronic) Receipt
Feb 16, 2016
Letter accompanying subsequently filed items
Feb 16, 2016
Reply to Written Opinion prepared by the EPO
Feb 2, 2016
Communication of amended entries concerning the representative
Jan 20, 2016
Submission concerning change of applicant's address
Sep 14, 2015
Reminder period for payment of examination fee/designation fee and correction of deficiencies in Written Opinion/amendment
Aug 12, 2015
Notification of forthcoming publication
Jun 22, 2015
Communication regarding the transmission of the European search report
Jun 22, 2015
European search opinion
Jun 22, 2015
European search report
Jun 15, 2015
Search started
May 20, 2015
Confirmation of receipt of (electronically) transmitted priority document
May 11, 2015
Priority document (electronically transmitted)
May 11, 2015
Priority document (electronically transmitted)
May 4, 2015
Communication to designated inventor
May 4, 2015
Communication to designated inventor
Mar 9, 2015
Abstract
Mar 9, 2015
Acknowledgement of receipt of electronic submission of the request for grant of a European patent
Mar 9, 2015
Claims
Mar 9, 2015
Description
Mar 9, 2015
Designation of inventor
Mar 9, 2015
Drawings
Mar 9, 2015
Request for grant of a European patent

EP2915526

GALENICUM HEALTH SL

Application Number: EP15158157A
Filing Date: Mar 9, 2015
Status: Granted And Under Opposition; Apr 30, 2021
Publication Date: Jun 2, 2021
External Links: Slate, Register , Google Patents

IP Verse

Pharmaceutical Compositions Comprising Anagrelide

Patent Summary

Patent Family

Patent Oppositions

Dossier Documents

EP2915526